Condition
EGFR Exon 19 Deletion Mutation
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownObservational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung CancerNCT07563205 · 2025-11-19
RECRUITINGUtilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer PatientsNCT06659458 · 2025-01-01
RECRUITINGBefotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC PatientsNCT07709585 · 2026-07-05
NOT_YET_RECRUITINGErlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor MutationsNCT01532089 · 2012-03-16
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
RECRUITING2
COMPLETED1
NOT_YET_RECRUITING1
Phase mix
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.